Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 4/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | DHODH | Q02127 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19691115 | 0.87 | PLA2G10 (0.61) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL7487026 | 0.87 | KDM4E (0.68) | MEN1KMT2AKDM4ENPC1MAPT | |
| SCHEMBL9203821 | 0.83 | KDM4E (0.64) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL9205486 | 0.83 | HTR3E (0.58) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL13490841 | 0.81 | KDM4E (0.55) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL7939470 | 0.80 | PDE10A (0.65) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL16832301 | 0.80 | DHODH (0.55) | MEN1KMT2AKDM4ELMNAALDH1A1 | |
| SCHEMBL31673005 | 0.79 | KDM4E (0.65) | KDM4ENPC1RAB9ALMNASMN1; SMN2 | |
| SCHEMBL9204352 | 0.79 | DHODH (0.63) | MEN1KMT2AKDM4ENPC1RAB9A | |
| SCHEMBL8618634 | 0.79 | DHODH (0.69) | MEN1KMT2AKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577243-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-17 | — | — | US | disclosed |
| EP-3856178-B1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2026-03-11 | — | — | EP | disclosed |
| US-20250236792-A1 | ETCHANT COMPOSITION FOR ETCHING SILICON AND METHOD OF FORMING PATTERN USING THE SAME | DONGWOO FINE-CHEM CO., LTD. (KR) | 2025-07-24 | — | — | US | disclosed |
| CN-115335378-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-113164459-B | Monoacylglycerol lipase modulators | 詹森药业有限公司 | 2024-09-03 | — | — | CN | disclosed |
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-11 | — | — | US | disclosed |
| US-11891387-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2024-02-06 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| EP-4126860-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| US-6699879-B1 | OBESITY, DIABETES, SLEEP DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-03-02 | — | — | US | disclosed |
| EP-1165084-A4 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO INC (US) | 2002-05-15 | — | — | EP | disclosed |
| EP-1165084-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | Merck & Co., Inc. (US) | 2002-01-02 | — | — | EP | disclosed |
| EP-1150977-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2001-11-07 | — | — | EP | disclosed |
| WO-2000051614-A1 | INHIBITORS OF PRENYL-PROTEIN TRANSFERASES | MERCK & CO., INC. (US) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000047577-A1 | PHENYL UREA AND PHENYL THIOUREA DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-17 | — | — | WO | disclosed |
| EP-0564650-B1 | QUINOLINE DERIVATIVE | KYOWA HAKKO KOGYO KK (JP) | 1995-09-20 | — | — | EP | disclosed |
| US-5319085-A | Antiemetic agents; anticarcinogenic agent-induced vomiting; antianxiolytic agents; psychological disorders | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1994-06-07 | — | — | US | disclosed |
| EP-0564650-A1 | QUINOLINE DERIVATIVE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| US-4970214-A | DIABETIC COMPLICATIONS | NIPPON SHINYAKU CO., LTD. (JP) | 1990-11-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228484-A1 | MONOACYLGLYCEROL LIPASE MODULATORS | MGLL, LPL, PNLIP | MEN1 2100/4885KMT2A 1490/4885KDM4E 3365/4885 |
| US-12577243-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, FAAH | MEN1 4537/4885KMT2A 3729/4885KDM4E 3565/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | MEN1 4128/4885KMT2A 1069/4885KDM4E 2437/4885 |
| US-11891387-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MEN1 2100/4885KMT2A 1490/4885KDM4E 3365/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | MEN1 4128/4885KMT2A 1069/4885KDM4E 2437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.